Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
A combination of mTOR inhibitor, ridaforolimus and novel AKT inhibitor, MK-2206, showed activity in heavily pretreated hormone positive and negative breast cancer patients who exhibit PI3K pathway dependence, based on low RAS signature score. The combination was well tolerated in a phase I study, according to Dr Shilpa Gupta of the Lee Moffitt Cancer Center, Tampa, USA.
Read the article in full here.
Source: ESMO
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.